Abstract
The ‘Precision Medicine for Cancer’ was the first meeting of a new series of conferences organised biannually by the European Association for Cancer Research (EACR) and the Organisation for European Cancer Institutes (OECI). The main objective of the meeting was to focus on novel topics in precision medicine by allowing strong interactions between participants and to access the speakers easily. As the first implementations of personalised medicine are appreciated in the clinic, the aim of the meeting was to further educate both researchers and clinicians and learn more from the novel approaches in the field. Similarly, the interaction between two organisations—the research-oriented EACR and the clinic-oriented OECI—was of a great value for the meeting. This OECI-EACR 2015 report will highlight the major findings of this outstanding meeting.
Highlights
The conference started with the welcoming words from the organisers: Professor Simone Niclou, the local organizer from the Luxembourg Institute of Health, the head of the NorLux Neuro Oncology laboratory; Professor Richard Marais, the head of the Molecular Oncology Lab, the Director of the CRUK Manchester Institute and the European Association for Cancer Research (EACR) President; and Professor Giorgio Stanta from the University of Trieste (Italy), representing the Organisation for European Cancer Institutes (OECI)
DNA damage response (DDR) kinases became activated following hypoxia and either the depletion or pharmacologic inhibition of DDR kinases were toxic to melanoma cells. This included resistance to the BRAF inhibitor, and this could be ecancer 2015, 9:519 enhanced by angiogenesis blockade. These results reveal that hypoxia sensitizes melanomas to targeted inhibition of the DDR showing the utility of in vivo short hairpin RNA (shRNA) dropout screens for the identification of pharmacologically tractable targets [31]
Precision Medicine is a novel approach for disease diagnosis and treatment that takes into account individual differences between patients
Summary
Professor Simone Niclou, the head of Norlux Neuro-Oncology laboratory at the Luxembourg Institute of Health (L.I.H), summarized our current understanding on very strong inter- and intra-tumoural heterogeneity in glioblastoma, the most aggressive and incurable type of brain tumours She presented current attempts to stratify the glioblastoma patients based on genetic profile, transcriptome, epigenome and altered molecular pathways. Dr Safia Thaminy presented the seventh proffered paper from the ETH in Zurich (Switzerland) and the Institute for Systems Biology, Seattle (USA) She studied the role of hypoxia in breast cancer and used breast cancer cell lines with distinct aggressiveness properties to develope an innovative strategy based on a system-wide quantitative proteomics in combination with a high-throughput migration screen and protein network analysis. He highlighted a role of cellular heterogeneity and paracrine cross-talk between different tumour cell types (NE and non-NE cells) in acquiring metastatic potential
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call